Osteoporosis After Extrarenal Transplantation: Pathogenesis, Prevention, and Management CME/CE

Author Information and Disclosures

Release Date: October 2, 2008; Valid for credit through October 2, 2009

Credits Available
Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians;
Nurses - 1.0 ANCC contact hours (0.5 contact hours are in the area of pharmacology);
Pharmacists - 1.0 ACPE continuing education credits for pharmacists (0.1 CEUs)

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

Legal Disclaimer

The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Copyright © 2008 Medscape.
Medscape
Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Describe the pathogenesis and histologic changes of osteoporosis
  2. Identify risk factors for poor bone health and osteoporosis in liver, heart, and lung transplant recipients
  3. Explain the importance of and methods for pre- and posttransplant screening for vitamin D deficiency and osteoporosis
  4. Identify first-line and adjunctive therapies for glucocorticoid-induced osteoporosis
Authors and Disclosures

Emily M. Stein, MD
Disclosure: Emily M. Stein, MD, has disclosed no relevant financial relationships.


Elizabeth Shane, MD
Disclosure: Elizabeth Shane, MD, has disclosed that she has received grants for clinical research from Novartis, Amgen, Aventis, Procter & Gamble, and Lilly Pharmaceuticals.


Susan Smith, MN, PhD
Disclosure: Susan Smith, MN, PhD, has disclosed no relevant financial relationships.
 
Medscape
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

Medscape is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Awarded 1.0 contact hour(s) of continuing nursing education for RNs and APNs; 0.5 contact hours are in the area of pharmacology.

Contact This Provider

 
ACPE logoMedscape is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Medscape designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) (Universal Program Number 461-000-08-053-H01-P).

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.